Genomic Response Analysis of Heart Failure Therapy in African Americans



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:1/9/2019
Start Date:May 2015
End Date:June 2019

Use our guide to learn which trials are right for you!

Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans

The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine
(FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction
(HFrEF) when compared to similar white cohorts. This study will seek to confirm the previous
genetic sub-study from AHeFT which suggested a functional polymorphism of guanine nucleotide
binding protein beta polypeptide 3 subunit (GNB3), C825T in exon 10, influences the
therapeutic efficacy of FDC I/H. This study will initiate treatment with FDC I/H in 500 self
designated African American subjects with systolic heart failure. They will be followed for
up to two years on therapy. Clinical outcomes (survival, heart failure hospitalizations, and
change in quality of life) on FDC I/H will be compared by GNB3 genotype subset. The
hypothesis to be confirmed is that subjects homozygous for the T allele (those with the GNB3
TT genotype which is present in approximately 50% of black subjects) demonstrate enhanced
therapeutic benefit from FDC I/H.

The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine
(FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction
(HFrEF) when compared to similar white cohorts. Despite the clear survival benefits of
treatment with FDC I/H in the African American Heart Failure Trial (AHeFT), the drug is
prescribed in only 25% of black subjects who would potentially benefit.

In terms of the enhanced response evident in the A-HeFT investigation, race is likely a
marker of differences in genomic background. Genetic variation of the G protein beta sub unit
GNB3 has been studied extensively for its role in hypertension. A polymorphism exists at
position 825 (T/C) which is functionally silent but tightly linked to a splicing variant
resulting in a truncated protein. The GNB3 T haplotype is far more prevalent in blacks and
associated with low renin hypertension. Evaluation of 350 subjects in the genetic sub-study
of AHeFT suggests that the GNB3 TT genotype, found in 50% of African Americans but only
10-15% of whites, was linked to an enhanced therapeutic response to FDC I/H. This
investigation will evaluate the hypothesis that the GNB3 TT genotype is a marker of enhanced
therapeutic response to FDC I/H in African Americans with HFrEF.

The study will enroll a cohort of 500 African Americans with HFrEF, initiate therapy with FDC
I/H and follow them for up to two years. Subjects will be genotyped at entry for the GNB3
polymorphism and response to therapy compared by genotype. Therapeutic response will be
quantified using the composite score, the primary endpoint of AHeFT, which incorporates
mortality, heart failure hospitalizations, and a change in quality of life (QoL) score at six
months.

Aim 2 will do a similar analysis of response to therapy by GNB3 genotype using improvement in
left ventricular end diastolic diameter (LVEDD) or left ventricular ejection fraction (LVEF)
by echocardiogram after six months on therapy as the outcomes measure. Aim 3 will use
admixture analysis to determine first how global ancestry (the % African ancestral DNA for an
individual) impacts on the outcome measures of drug response, and how the global ancestry
acts as a modifier for the effect of GNB3.

Inclusion Criteria:

1. 18 years and older

2. History of heart failure with an LVEF (less than OR equal to) < 0.35 for at least 6
months OR an LVEF < 0.45 with left ventricular internal end diastole (defined by a
diameter of more than 2.9 cm per square meter of body surface area OR more than 6.5 cm
on the basis of echocardiography). ** Echo must be done within 6 months of
enrollment**

3. New York Heart Association (NYHA) Class II-IV

4. Background heart failure therapy that includes angiotensin converting enzyme
inhibitors (ACEi) or angiotensin receptor blockers (ARBs), and beta blockers (BBs) for
at least 3 months (or documentation of intolerance to ACEi/ARBs and BBs)

5. Self-designated race as African American or black (would include subjects whose
country of origin was outside the USA such as Africa, the Caribbean, or Central
America).

Exclusion Criteria:

1. History of intolerance to either nitrates or hydralazine

2. Treatment with the combination of hydralazine and nitrates for the previous 3 months

3. Revascularization or myocardial infarction within last 90 days

4. Received cardiac resynchronization therapy (CRT) AND did not have an assessment of
cardiac function documenting an LVEF < 35% (less than OR equal to 35%) at least 90
days post CRT

5. Presence of clinically significant valvular heart disease, hypertrophic or restrictive
cardiomyopathy, active myocarditis, or uncontrolled hypertension. (Note that
uncontrolled hypertension is defined as blood pressure consistenly greater than 160
mmHg systolic and 95 mmHg diastolic)

6. Women who are currently pregnant, planning on becoming pregnant in the next two years,
or those who do not agree to prevent pregnancy.

7. Subjects who are on continuous home inotropes, a left ventricular assist device, or
who are post cardiac transplant.
We found this trial at
19
sites
Tuscaloosa, Alabama 35401
Principal Investigator: Sumanth D Prabhu, MD
Phone: 205-934-8767
?
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Alanna Morris, M.D.
Phone: 404-712-1961
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Biykem Bozkuert, MD
Phone: 713-794-8757
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Atlanta, Georgia
Principal Investigator: Adeisayo Oduwole, MD
Phone: 404-616-8851
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
Principal Investigator: Gautam V Ramani, MD
Phone: 410-328-7623
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Christopher Newton-Cheh, M.D.
Phone: 617-643-6328
?
mi
from
Boston, MA
Click here to add this to my saved trials
111 East 210th Street
Bronx, New York 10461
Principal Investigator: James M Tauras, M.D.
Phone: 718-904-3293
?
mi
from
Bronx, NY
Click here to add this to my saved trials
96 Jonathan Lucas Street
Charleston, South Carolina 29425
Principal Investigator: Adrian Van Bakel, M.D.
Phone: 843-792-2944
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Andrew Buda, M.D.
Phone: 434-982-1058
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Allen Anderson, MD
Phone: 312-695-4189
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
Principal Investigator: Christopher Gans, M.D.
Phone: 312-413-2948
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44109
Phone: 216-778-2223
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: David Lanfear, MD
Phone: 313-916-3502
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Frank McGrew, MD
Phone: 901-271-4064
?
mi
from
Germantown, TN
Click here to add this to my saved trials
1415 Tulane Avenue
New Orleans, Louisiana 70112
Principal Investigator: Keith Ferninand, M.D.
Phone: 504-988-2030
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Hector Ventura, M.D.
Phone: 504-842-5257
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Newark, New Jersey 07102
Principal Investigator: Pallavi Solanki, MD
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19140
Principal Investigator: Deborah Crabbe, MD
Phone: 215-707-8191
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Principal Investigator: Dennis McNamara, MD
Phone: 412-692-4828
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials